Inhibikase Therapeutics, Inc. Annual report [Section 13 and 15(d), not S-K Item 405]

Annual report [Section 13 and 15(d), not S-K Item 405]

Net Loss Per Share

Net Loss Per Share

12 Months Ended

Dec. 31, 2024

12. Net Loss Per Share

The following table presents the calculation of basic and diluted net loss per share applicable to common stockholders. Basic net loss per share is calculated by dividing net loss attributable to common shareholders by the weighted-average number of shares outstanding during the period which includes Pre-Funded Warrants and shares held in abeyance from date of issuance.


	Year ended December 31,
	2024			2023
Numerator:
Net loss	$	(27,519,886	)	$	(19,028,883	)
Denominator:
Weighted-average number of common shares outstanding – basic and diluted		23,712,220			6,028,210
Net loss per share applicable to common stockholders – basic and diluted	$	(1.16	)	$	(3.16	)

The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock method, because their effect would have been anti-dilutive for the periods presented:


	Year ended December 31,
	2024		2023
Options to purchase shares of stock		16,904,050		839,523
Warrants to purchase shares of stock		26,134,671		2,266,133
Total		43,038,721		3,105,656